2seventy bio (TSVT) Reports Preliminary Full-Year U.S. Abecma Sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
February 6, 2025 7:03 AM EST$242 million in U.S. Abecma sales in 2024
Approximately $184 million of cash, cash equivalents and marketable securities as of December 31, 2024
Net cash burn of $9 million in the fourth quarter of 2024; path to quarterly breakeven by the end of 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq:... More
